S&P 500   4,564.02 (-0.13%)
DOW   36,114.86 (-0.25%)
QQQ   386.33 (+0.00%)
AAPL   193.02 (+1.90%)
MSFT   371.66 (+0.68%)
META   316.86 (-0.99%)
GOOGL   130.50 (+0.95%)
AMZN   146.65 (+1.25%)
TSLA   238.94 (+1.43%)
NVDA   462.10 (+1.54%)
NIO   7.53 (+2.87%)
BABA   72.37 (-0.90%)
AMD   117.92 (-0.55%)
T   17.25 (+3.54%)
F   10.61 (-0.84%)
MU   73.63 (-0.89%)
CGC   0.67 (-11.45%)
GE   120.85 (-0.56%)
DIS   90.34 (-1.82%)
AMC   7.00 (-6.54%)
PFE   29.23 (-0.17%)
PYPL   57.63 (-3.71%)
XOM   101.07 (-1.33%)
S&P 500   4,564.02 (-0.13%)
DOW   36,114.86 (-0.25%)
QQQ   386.33 (+0.00%)
AAPL   193.02 (+1.90%)
MSFT   371.66 (+0.68%)
META   316.86 (-0.99%)
GOOGL   130.50 (+0.95%)
AMZN   146.65 (+1.25%)
TSLA   238.94 (+1.43%)
NVDA   462.10 (+1.54%)
NIO   7.53 (+2.87%)
BABA   72.37 (-0.90%)
AMD   117.92 (-0.55%)
T   17.25 (+3.54%)
F   10.61 (-0.84%)
MU   73.63 (-0.89%)
CGC   0.67 (-11.45%)
GE   120.85 (-0.56%)
DIS   90.34 (-1.82%)
AMC   7.00 (-6.54%)
PFE   29.23 (-0.17%)
PYPL   57.63 (-3.71%)
XOM   101.07 (-1.33%)
S&P 500   4,564.02 (-0.13%)
DOW   36,114.86 (-0.25%)
QQQ   386.33 (+0.00%)
AAPL   193.02 (+1.90%)
MSFT   371.66 (+0.68%)
META   316.86 (-0.99%)
GOOGL   130.50 (+0.95%)
AMZN   146.65 (+1.25%)
TSLA   238.94 (+1.43%)
NVDA   462.10 (+1.54%)
NIO   7.53 (+2.87%)
BABA   72.37 (-0.90%)
AMD   117.92 (-0.55%)
T   17.25 (+3.54%)
F   10.61 (-0.84%)
MU   73.63 (-0.89%)
CGC   0.67 (-11.45%)
GE   120.85 (-0.56%)
DIS   90.34 (-1.82%)
AMC   7.00 (-6.54%)
PFE   29.23 (-0.17%)
PYPL   57.63 (-3.71%)
XOM   101.07 (-1.33%)
S&P 500   4,564.02 (-0.13%)
DOW   36,114.86 (-0.25%)
QQQ   386.33 (+0.00%)
AAPL   193.02 (+1.90%)
MSFT   371.66 (+0.68%)
META   316.86 (-0.99%)
GOOGL   130.50 (+0.95%)
AMZN   146.65 (+1.25%)
TSLA   238.94 (+1.43%)
NVDA   462.10 (+1.54%)
NIO   7.53 (+2.87%)
BABA   72.37 (-0.90%)
AMD   117.92 (-0.55%)
T   17.25 (+3.54%)
F   10.61 (-0.84%)
MU   73.63 (-0.89%)
CGC   0.67 (-11.45%)
GE   120.85 (-0.56%)
DIS   90.34 (-1.82%)
AMC   7.00 (-6.54%)
PFE   29.23 (-0.17%)
PYPL   57.63 (-3.71%)
XOM   101.07 (-1.33%)

Exagen Stock Price, News & Analysis (NASDAQ:XGN)

$1.86
+0.05 (+2.76%)
(As of 01:37 PM ET)
Compare
Today's Range
$1.79
$1.93
50-Day Range
$1.45
$2.53
52-Week Range
$1.33
$3.92
Volume
11,255 shs
Average Volume
20,478 shs
Market Capitalization
$31.71 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.50

Exagen MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
200.5% Upside
$5.50 Price Target
Short Interest
Healthy
0.09% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.29
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
Selling Shares
$59,183 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($1.46) to ($1.41) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.44 out of 5 stars

Medical Sector

79th out of 949 stocks

Medical Laboratories Industry

2nd out of 21 stocks


XGN stock logo

About Exagen Stock (NASDAQ:XGN)

Exagen Inc. develops and commercializes various testing products based on its cell-bound complement activation products technology under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its lead testing product is AVISE CTD that enables differential diagnosis for patients presenting with symptoms indicative of various connective tissue diseases (CTDs) and other related diseases with overlapping symptoms. The company offers AVISE Lupus that measures activation of the complement system by quantifying the level of B-cell C4d and erythrocyte bound C4d in the patient's blood; and AVISE APS, which consists of a panel of autoantibody tests that aids in the diagnosis and management of APS. In addition, it provides AVISE Vasculitis AAV, which utilizes a testing panel of individual analytes to provide physicians with results in the assessment and monitoring of anti-neutrophil cytoplasmic antibody associated vasculitis; AVISE SLE Prognostic, a panel of autoantibodies for assessing the potential for complications affecting the kidney, brain, and cardiovascular system; AVISE Anti-CarP test, which identifies RA patients with severe disease; and AVISE PC4d to measure platelet- bound C4d. Further, the company offers AVISE SLE Monitor, a biomarker blood test; AVISE MTX, a patented and validated blood test; and AVISE HCQ, a blood test to monitor levels of hydroxychloroquine. It has a research collaboration and license agreement with Allegheny Health Network (AHN) Research Institute to develop novel patented biomarkers. The company was formerly known as Exagen Diagnostics, Inc. and changed its name to Exagen Inc. in January 2019. Exagen Inc. was incorporated in 2002 and is headquartered in Vista, California.

XGN Stock Price History

XGN Stock News Headlines

New CBOE “special perk” helps traders target income every weekend
You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange.
Exagen Inc. Reports Strong Third Quarter 2023 Results
Here's what to expect from Exagen's earnings report
Earnings Preview For Exagen
Trading Experts Call It “The Perfect Tesla Trade”
Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.
Exagen Inc Ordinary Shares XGN
Exagen Inc. Reports Strong Second Quarter 2023 Results
Exagen's Earnings Outlook
Exagen Inc. Appoints Paul Kim to Board of Directors
See More Headlines
Receive XGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Exagen and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/10/2021
Today
12/05/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
3/18/2024

Industry, Sector and Symbol

Industry
Medical laboratories
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:XGN
Fax
N/A
Employees
199
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$5.50
High Stock Price Target
$6.00
Low Stock Price Target
$5.00
Potential Upside/Downside
+200.5%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-47,390,000.00
Pretax Margin
-63.45%

Debt

Sales & Book Value

Annual Sales
$45.56 million
Book Value
$2.61 per share

Miscellaneous

Free Float
10,773,000
Market Cap
$31.20 million
Optionable
Not Optionable
Beta
1.21
5G Stocks: The Path Forward is Profitable Cover

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Key Executives

  • Dr. Tina S. Nova Ph.D. (Age 69)
    Executive Chairman of Board
    Comp: $65k
  • Mr. John Aballi (Age 38)
    CEO, President & Director
    Comp: $558.84k
  • Mr. Kamal Adawi M.S. (Age 44)
    MBA, CFO & Corporate Secretary
    Comp: $483.28k
  • Mr. Mark Hazeltine (Age 49)
    Chief Business Officer
    Comp: $483.28k
  • Ryan Douglas
    Investors Relations Officer
  • Mr. John Wegener (Age 54)
    Senior Vice President of Sales and Marketing
  • Dr. Andrew L. Concoff FACR
    M.D., Chief Innovation Officer & Member of Rheumatoid Arthritis Scientific Advisory Board
  • Dr. Michael I. Nerenberg M.D. (Age 68)
    Chief Medical Officer














XGN Stock Analysis - Frequently Asked Questions

Should I buy or sell Exagen stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Exagen in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" XGN shares.
View XGN analyst ratings
or view top-rated stocks.

What is Exagen's stock price target for 2024?

3 brokers have issued 1-year price targets for Exagen's shares. Their XGN share price targets range from $5.00 to $6.00. On average, they predict the company's stock price to reach $5.50 in the next year. This suggests a possible upside of 200.5% from the stock's current price.
View analysts price targets for XGN
or view top-rated stocks among Wall Street analysts.

How have XGN shares performed in 2023?

Exagen's stock was trading at $2.40 at the start of the year. Since then, XGN stock has decreased by 23.8% and is now trading at $1.83.
View the best growth stocks for 2023 here
.

When is Exagen's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, March 18th 2024.
View our XGN earnings forecast
.

How were Exagen's earnings last quarter?

Exagen Inc. (NASDAQ:XGN) announced its earnings results on Wednesday, November, 10th. The company reported ($0.42) earnings per share for the quarter, beating the consensus estimate of ($0.46) by $0.04. The company earned $12.25 million during the quarter, compared to analysts' expectations of $12.13 million. Exagen had a negative trailing twelve-month return on equity of 81.62% and a negative net margin of 62.90%. During the same period in the prior year, the company earned ($0.34) EPS.

What guidance has Exagen issued on next quarter's earnings?

Exagen issued an update on its FY 2023 earnings guidance on Monday, November, 13th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $50.00M-, compared to the consensus revenue estimate of $46.76 million.

What is Ron Rocca's approval rating as Exagen's CEO?

5 employees have rated Exagen Chief Executive Officer Ron Rocca on Glassdoor.com. Ron Rocca has an approval rating of 80% among the company's employees.

When did Exagen IPO?

(XGN) raised $50 million in an IPO on Thursday, September 19th 2019. The company issued 3,300,000 shares at a price of $14.00-$16.00 per share. Cowen, Cantor and William Blair served as the underwriters for the IPO.

Who are Exagen's major shareholders?

Exagen's stock is owned by many different institutional and retail investors. Top institutional investors include Stonepine Capital Management LLC (7.14%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Hunt Holdings Limited Partners, James L L Tullis, John Aballi, Mark Hazeltine, Nmsic Co-Investment Fund, LP and Wendy S Johnson.
View institutional ownership trends
.

How do I buy shares of Exagen?

Shares of XGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:XGN) was last updated on 12/5/2023 by MarketBeat.com Staff

My Account -